2. Search Result
Search Result
Results for "

FOXM1

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

5

Peptides

1

Natural
Products

1

Recombinant Proteins

3

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0990
    Thiostrepton
    20+ Cited Publications

    		 Bacterial Antibiotic YAP Infection
    Thiostrepton is a thiazole antibiotic which selectively inhibits FOXM1. FOXM1 binds to YAP/TEAD complex. YAP/TEAD/FOXM1 complex binding at regulatory regions of genes governing cell cycle may impact cell proliferation [1].
    Thiostrepton
  • HY-112721
    FDI-6
    5+ Cited Publications

    		 DNA/RNA Synthesis Cancer
    FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.
    FDI-6
  • HY-19979
    RCM-1
    5+ Cited Publications

    		 DNA/RNA Synthesis Cancer
    RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research [1].
    RCM-1
  • HY-148530
    YX-2-107

    		PROTACs CDK Cancer
    YX-2-107 is a PROTAC (IC50= 4.4 nM) that selectively degrades CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph + ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph +) acute lymphoblastic leukemia (ALL) [1].
    YX-2-107
  • HY-151986
    FOXM1-IN-1

    		DNA/RNA Synthesis Cancer
    FOXM1-IN-1 is a potent FOXM1 inhibitor with an IC50 value of 2.65 µM. FOXM1-IN-1 shows antiproliferative activity. FOXM1-IN-1 decreases the the expression of FOXM1, PLK1, CDC25B protein [1].
    FOXM1-IN-1
  • HY-158420
    STL001

    		Autophagy Cancer
    STL001 is potent and selective FOXM1 inhibitor. STL001 induces the translocation of nuclear FOXM1 to the cytoplasm and promotes its autophagic degradation. STL001 sensitizes human cancers to a broad-spectrum of cancer therapies [1].
    STL001
  • HY-153916
    TCRS-417
    1 Publications Verification

    T417

    		 HOXA DNA/RNA Synthesis NEKs Neurological Disease Inflammation/Immunology Cancer
    TCRS-417 (T417) is a small-molecular inhibitor for PBX1. TCRS-417 can directly block PBX1-binding to DNA (IC50 = 6.58 μM), and affects PBX1 transcription. TCRS-417 is able to hammer out the stemness traits of Carboplatin (HY-17393)-resistant (CR) cells to revert to a differentiated status through tacking PBX1 signaling cascade. TCRS-417 significantly suppresses self-renewal and proliferation of cancer cells expressing high levels of PBX1. TCRS-417 can decrease the mRNA levels of FOXM1, NEK2, and E2F2 in cancer cell lines. TCRS-417 is selectively toxic against chr1q-amp myeloma and solid tumor cells [1] .
    TCRS-417
  • HY-P11228
    FPP29

    		PROTACs Apoptosis DNA/RNA Synthesis Cancer
    FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)) [1].
    FPP29
  • HY-RS05064
    FOXM1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    FOXM1 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FOXM1 Human Pre-designed siRNA Set A
    FOXM1 Human Pre-designed siRNA Set A
  • HY-117522
    Sepin-1
    2 Publications Verification

    		 Separase Cancer
    Sepin-1 is a potent separase inhibitor with an IC50 value of 14.8 µM. Sepin-1 inhibits cell proliferation, migration and wound healing. Sepin-1 decreases the expression of FoxM1 protein and mRNA level. Sepin-1 shows anti-tumor activity [1] .
    Sepin-1
  • HY-149145
    Ena15

    		Anaplastic lymphoma kinase (ALK) Fat Mass and Obesity-associated Protein (FTO) Cancer
    Ena15 is an ALKBH5 inhibitor. Ena15 enhances the demethylase activity of FTO. Ena15 increases m 6A RNA level, and stabilizes FOXM1 mRNA. Ena15 suppresses the growth activity of glioblastoma multiforme [1].
    Ena15
  • HY-178462
    Hsp70/FoxM1-IN-1

    		HSP DNA/RNA Synthesis Cancer
    Hsp70/FoxM1-IN-1 (Compound 7d) is a potent heat shock protein 70 (Hsp70) and Forkhead box M1 (FoxM1) dual inhibitor. Hsp70/FoxM1-IN-1 demonstrates significant antiproliferative and pro-apoptotic effects in multiple solid tumor models (e.g., breast, colorectal cancer), particularly for tumors co-overexpressing Hsp70/FoxM1 [1].
    Hsp70/FoxM1-IN-1
  • HY-170944
    BAG3/HSP70-IN-1

    		HSP Apoptosis Caspase Cancer
    BAG3/HSP70-IN-1 (compound 16) is the first-in-class BAG3 and HSP70 dual inhibitor. BAG3/HSP70-IN-1 binds to BAG3 full-length, BAG3-BD, and HSP70 proteins with Kds of 33.10 μM, 27.90 μM, and 33.80 μM, respectively. BAG3/HSP70-IN-1 inhibits HeLa cells with an IC50 of 49.46 μM. BAG3/HSP70-IN-1 induces apoptosis by activating caspase 3 and caspase 9 levels in HeLa cells. BAG3/HSP70-IN-1 elevates p21 levels while reduces FOXM1 expression in HeLa cells. BAG3/HSP70-IN-1 decreases ATPase activity [1].
    BAG3/HSP70-IN-1
  • HY-P1687
    Siomycin A

    		Bacterial Apoptosis Cancer
    Siomycin A is a thiopeptide antibiotic and is a Forkhead box M1(FOXM1) selective inhibitor without affecting other members of the Forkhead box family. Siomycin A has anti-tumor and promotes apoptosis [1] .
    Siomycin A
  • HY-RS23075
    Foxm1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Foxm1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxm1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Foxm1 Rat Pre-designed siRNA Set A
    Foxm1 Rat Pre-designed siRNA Set A
  • HY-P10553
    ARF(26–44), cell-permeable

    		Apoptosis Cancer
    ARF(26–44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable can be used in research on tumor therapy [1].
    ARF(26–44), cell-permeable
  • HY-RS16641
    Foxm1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Foxm1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxm1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Foxm1 Mouse Pre-designed siRNA Set A
    Foxm1 Mouse Pre-designed siRNA Set A
  • HY-P11494
    AWWNTEW

    CP29 peptide

    		 DNA/RNA Synthesis Ligands for Target Protein for PROTAC Cancer
    AWWNTEW (CP29) is a FOXM1-DBD peptide ligand with cytotoxicity to cancer cells. AWWNTEW has a strong affinity and binds to the FOXM1 protein. AWWNTEW is a component of FPP29 (HY-P11228) [1]. X
    AWWNTEW
  • HY-156609
    FOXM1-IN-2

    		DNA/RNA Synthesis Cancer
    FOXM1-IN-2 is a FOXM1 inhibitor, with antineoplastic activity [1].
    FOXM1-IN-2
  • HY-112509
    STL427944

    		Autophagy Cancer
    STL427944 is a potent and selective FOXM1 inhibitor. STL427944 has the potential for the research of overcoming tumor chemoresistance [1].
    STL427944
  • HY-182285
    FOXM1-IN-4

    		5-HT Receptor DNA/RNA Synthesis Cancer
    FOXM1-IN-4 is a selective 5-HT7 receptor inhibitor with a Ki of 92 nM. FOXM1-IN-4 blocks 5-HT7 receptor signaling to reduce FOXM1, p-FOXM1, cyclin B1, and cdc25B levels. FOXM1-IN-4 acts as an antiproliferative, clonogenic inhibitor, and cell cycle inhibitor that induces G2/M arrest, reduces G0/G1 population. FOXM1-IN-4 can be used for the research of triple-negative breast cancer [1].
    FOXM1-IN-4
  • HY-P10553A
    ARF(26–44), cell-permeable acetate

    		Apoptosis Cancer
    ARF(26–44), cell-permeable acetate is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable acetate shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable acetate can be used in research on tumor therapy [1].
    ARF(26–44), cell-permeable acetate
  • HY-181076
    FOXM1-IN-3

    		PI3K CDK Apoptosis Cancer
    FOXM1-IN-3 is a potent FOXM1 inhibitor. FOXM1-IN-3 downregulates FOXM1 expression at protein and mRNA levels, suppressing downstream effectors CCNB1 and CDC25. FOXM1-IN-3 induces G2/M cell cycle arrest and apoptosis in colorectal cancer cells. FOXM1-IN-3 inhibits colony formation and cell migration in colorectal cancer cells. FOXM1-IN-3 targets the cancer stem cell phenotype in colorectal cancer cells, reducing cancer stem cell marker expression. FOXM1-IN-3 reduces tumor growth in a zebrafish xenograft model. FOXM1-IN-3 can be used for the research of colorectal cancer [1].
    FOXM1-IN-3
  • HY-150038
    NOSH-aspirin

    NBS-1120

    		 NF-κB Apoptosis Neurological Disease Cancer
    NOSH-aspirin (NBS-1120) is an orally active hybrid molecule that releases nitric oxide and hydrogen sulfide. NOSH-aspirin inhibits pancreatic cancer cell proliferation and induces apoptosis. NOSH-aspirin inhibits cancer cell growth and suppresses NF-κB and FoxM1 in a mouse model of pancreatic cancer. NOSH-aspirin also alleviates motor deficits and dopaminergic neuron degeneration in a rat model of Parkinson's disease. NOSH-aspirin reduces neuroinflammation caused by microglial and astrocytic activation. NOSH-aspirin can be used in research on cancers such as pancreatic cancer and neurological diseases such as Parkinson's disease [1] .
    NOSH-aspirin
  • HY-182285A
    FOXM1-IN-4 hydrochloride

    		5-HT Receptor DNA/RNA Synthesis Cancer
    FOXM1-IN-4 hydrochloride is a selective 5-HT7 receptor inhibitor with a Ki of 92 nM. FOXM1-IN-4 hydrochloride blocks 5-HT7 receptor signaling to reduce FOXM1, p-FOXM1, cyclin B1, and cdc25B levels. FOXM1-IN-4 hydrochloride acts as an antiproliferative, clonogenic inhibitor, and cell cycle inhibitor that induces G2/M arrest, reduces G0/G1 population. FOXM1-IN-4 hydrochloride can be used for the research of triple-negative breast cancer [1].
    FOXM1-IN-4 hydrochloride
  • HY-170552
    KC12

    		DNA/RNA Synthesis Cancer
    KC12 is an inhibitor for FOXM1 transcription factor. KC12 exhibits cytotoxicity in cancer cell MDA-MB-231 with an IC50 of 6.13 µM [1].
    KC12
  • HY-161617
    LASSBio-2052

    		DNA/RNA Synthesis Apoptosis Cancer
    LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells [1].
    LASSBio-2052

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: